Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Becton DickinsonXSWX:BDX 78 3-Year EBITDA Growth Rate is 3.80% as of Mar. 2026, which is 54% below its 10-year median of 8.20. GuruFocus rates XSWX:BDX with a GF Score™ of 78/100 and a GF Value™ of CHF150.54. The stock has 7 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Becton Dickinson ranks worse than 58.53% on this metric.
During the past 12 months, Becton Dickinson's average EBITDA Per Share Growth Rate was 8.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Becton Dickinson was 18.10% per year. The lowest was -2.20% per year. And the median was 8.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Becton Dickinson 3-Year EBITDA Growth Rate Related Terms
XSWX:BDX vs MDLN, RMD, WST: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Becton Dickinson's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.80% mean?
Becton Dickinson (XSWX:BDX) has a 3-Year EBITDA Growth Rate of 3.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Becton Dickinson and its competitors. This is 54% below median its historical median of 8.20. According to the industry distribution chart, Becton Dickinson ranks #405 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 58.5%.
Is Becton Dickinson's 3-Year EBITDA Growth Rate too high?
Becton Dickinson's current 3-Year EBITDA Growth Rate of 3.80% is 54% below median its 10-year median of 8.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Becton Dickinson's value of 3.80% is 53.7% below this industry median. Based on the distribution chart, Becton Dickinson ranks #405 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Becton Dickinson has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's 3-Year EBITDA Growth Rate compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #405 out of 692 companies for 3-Year EBITDA Growth Rate. This places Becton Dickinson in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Becton Dickinson's value of 3.80% is 53.7% below this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 8.20, Becton Dickinson has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current 3-Year EBITDA Growth Rate of 3.80% is 53.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Becton Dickinson and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current 3-Year EBITDA Growth Rate is 3.80%, which is 54% below median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Becton Dickinson (XSWX:BDX) has a current 3-Year EBITDA Growth Rate of 3.80%. The stock's GF Value™ is CHF150.54, compared to a current price of CHF137.08 — trading 8.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.80%, which is 54% below median its 10-year median of 8.20 and 53.7% below the Medical Devices & Instruments industry median of 8.20. Becton Dickinson's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Becton Dickinson (XSWX:BDX), the current 3-Year EBITDA Growth Rate is 3.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (XSWX:BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of CHF137.08 is trading 8.9% below its estimated GF Value™ of CHF150.54.
Key valuation signals for XSWX:BDX:
3-Year EBITDA Growth Rate: 3.80% (54% below median its 10-year median of 8.20)
GF Value™: CHF150.54 vs. price of CHF137.08 (8.9% below fair value)
Industry Position: 53.7% below the Medical Devices & Instruments median (#405 of 692)
No single metric tells the full story. See the XSWX:BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
78GF Score
Get the complete analysis for XSWX:BDX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BDX has been successfully added to your 
